Peptide extracts from the Arctic prawnPandalus Borealishave demonstrated blood pressure benefits via the,most potent Angiotensin Converting Enzyme (ACE) inhibiting peptide concentrate that is reported in scientific literature.<\/p>\n
Those results in a small rat study, published in volume 46 of Process Biochemistry in 2011, have prompted a human clinical to be commissioned by the same Norwegian organisation - Nofima . <\/p>\n
That hydrolysates-peptides study is due to complete by years end. <\/p>\n
ACE inhibitors work by inhibiting the conversion of angiotensin I to the potent vasoconstrictor, angiotensin II, thereby improving blood flow and blood pressure. <\/p>\n
Nofima senior scientist and lead author of the study, Asbjrn Gildberg, said the ACE results were significant, although not necessarily linked just to the particular type of shrimp-prawn. <\/p>\n
These are the highest seen but hydrolysates from Chinese shrimps have indicated levels almost as good, he said.The human trial data will be very interesting. <\/p>\n
Results <\/p>\n
The researchers wrote: The measurements by two independent methods both revealed higherin vitroACE inhibitory activity, IC50=0.075 and 0.035mg\/ml, respectively, than earlier reported in comparable hydrolysates. <\/p>\n
An introductory feeding trial with spontaneously hypertensive rats indicated positivein vivoresults when the rats were given 60mg hydrolysate\/kg body weight per day. <\/p>\n
Although furtherin vivostudies are necessary to verify the antihypertensive potential, the very highin vitroACE inhibitory activity reveals that the shrimp protein hydrolysate is a promising candidate for nutraceutical application. <\/p>\n<\/p>\n
Read more: Peptide extracts from the Arctic prawnPandalus Borealishave demonstrated blood pressure benefits via the,most potent Angiotensin Converting Enzyme (ACE) inhibiting peptide concentrate that is reported in scientific literature. Those results in a small rat study, published in volume 46 of Process Biochemistry in 2011, have prompted a human clinical to be commissioned by the same Norwegian organisation - Nofima . That hydrolysates-peptides study is due to complete by years end. Continue reading
\nPrawn peptides are ACE for blood pressure: Rat study<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"